• PHP32 ANALYSIS OF PHARMACISTS' INTERVENTIONS ON ELECTRONIC VERSUS TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES

    May 1, 2011, 00:00

  • PDB64 EVALUATION OF THE BURDEN OF ILLNESS OF TYPE-2 DIABETES MELLITUS IN A MEDICARE POPULATION

    May 1, 2011, 00:00

  • PND61 EVALUATION OF CONSISTENCY BETWEEN MULTIPLE SCLEROSIS REGISTRY PUBLICATIONS

    May 1, 2011, 00:00

  • PCN31 DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY

    May 1, 2011, 00:00

  • PRM35 DEVELOPMENT OF A CONCEPT LIST TO ENSURE COMPARABLE CONTENT VALIDITY BETWEEN ORIGINAL PRO QUESTIONNAIRES AND THEIR TRANSLATIONS- A REVIEW OF 15 YEARS OF LINGUISTIC VALIDATIONS

    May 1, 2011, 00:00

  • PCV22 META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY AND EFFICACY OF DALTEPARIN TO ENOXAPARIN IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE

    May 1, 2011, 00:00

  • PCN62 BAYESIAN MODELLING ASSESSING THE EFFECTIVENESS OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES- THE BEST STUDY

    May 1, 2011, 00:00

  • PHP95 EXPECTED CHANGES IN HEALTH CARE UTILIZATION DUE TO PATIENT PROTECTION AND AFFORDABLE CARE ACT

    May 1, 2011, 00:00

  • PRM49 TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH

    May 1, 2011, 00:00

  • PMH22 CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

    May 1, 2011, 00:00

  • PCV65 NEW STATIN USERS' PERSISTENCE AND ADHERENCE- BOTH ARE CRITICAL CONCEPTS IN THE COMPREHENSIVE CHARACTERIZATION OF MEDICATION EXPOSURE

    May 1, 2011, 00:00

  • PMH39 COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPIES IN KOREA

    May 1, 2011, 00:00

  • PMH45 MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PMH68 FDA REGULATIONS AND ANTIDEPRESSANT UTILIZATION

    May 1, 2011, 00:00

  • PHP101 VALUE BASED PRICING- WHAT IS THE FUTURE FOR PATIENT ACCESS SCHEMES?

    May 1, 2011, 00:00

  • PRM14 VALIDATING AN ONLINE CALCULATOR FOR EVALUATING HEALTH INTERVENTION OPTIONS USING THE ANALYTIC HIERARCHY PROCESS (AHP)

    May 1, 2011, 00:00

  • PIN7 EPIDEMIOLOGY OF HIV-RELATED NEUROPATHY – A SYSTEMATIC LITERATURE REVIEW

    May 1, 2011, 00:00

  • PCN84 PATIENTS' PREFERENCES FOR THE TREATMENT OF COLORECTAL CANCER- A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY

    May 1, 2011, 00:00

  • PMS28 COST-EFFECTIVNESS ANALYSIS OF NSAIDS FOR SYMTOMATIC TREATMENT OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS

    May 1, 2011, 00:00

  • PHP78 CHARACTERISTICS OF HOMELESS INDIVIDUALS USING INPATIENT AND EMERGENCY DEPARTMENT SERVICES

    May 1, 2011, 00:00

  • PSS2 DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • PND45 ONE YEAR OF NATALIZUMAB TREATMENT IS ASSOCIATED WITH AN IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS

    May 1, 2011, 00:00

  • PCV2 THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS

    May 1, 2011, 00:00

  • PCV66 ADHERENCE RATES AMONG HEALTH PLAN MEMBERS STARTING GENERIC VERSUS BRAND STATIN THERAPY

    May 1, 2011, 00:00

  • PMH2 RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES

    May 1, 2011, 00:00

  • SB4 A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL STUDIES

    May 1, 2011, 00:00

  • QA2 CROSS-WALKING CANCER-SPECIFIC INSTRUMENTS TO THE EQ-5D AND SF-6D

    May 1, 2011, 00:00

  • PSS9 COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING

    May 1, 2011, 00:00

  • PUK1 INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION

    May 1, 2011, 00:00

  • PRS11 ESTIMATING THE ECONOMIC BURDEN OF FOOD-INDUCED ALLERGIC REACTIONS AND ANAPHYLAXIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • CO4 POTENTIAL COST SAVINGS FROM COMPARATIVE EFFECTIVENESS RESEARCH- LESSONS FROM COURAGE STUDY

    May 1, 2011, 00:00

  • PIN23 COST-EFFECTIVENESS OF ATAZANAVIR/RITONAVIR (ATV+RTV) COMPARED WITH LOPINAVIR/RITONAVIR (LPV+RTV) IN TREATMENT-NAÏVE HIV-INFECTED PATIENTS IN MEXICO- A MODEL BASED ON THE CASTLE STUDY

    May 1, 2011, 00:00

  • PCV5 PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN THE MEDICARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSY1 SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA

    May 1, 2011, 00:00

  • PDB58 WHAT IS THE IMPACT OF GENERIC SUBSTITUTION OF ROSIGLITAZONE ON PATIENT OUTCOMES AND TREATMENT COSTS? AN HMO EXPERIENCE

    May 1, 2011, 00:00

  • PCN43 STUDY ON MEDICAL EXPENDITURE AND PAYMENT PATTERNS OF INSURED PATIENTS WITH CANCER IN CHINA

    May 1, 2011, 00:00

  • PDB61 DECOMPOSING GENDER DIFFERENCES IN ANGIOTENSIN II CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS AMONG VETERANS WITH DIABETES

    May 1, 2011, 00:00

  • PDB59 THE COMPLEXITY OF DRUG THERAPY AND SOCIO-ECONOMIC VARIANTS IN PATIENTS WITH DIABETES

    May 1, 2011, 00:00

  • PCV7 ANALYSIS OF TREATMENT PATTERNS AND COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENTS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PSY26 IMPACT OF HYPONATREMIA ON PATIENT OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS

    May 1, 2011, 00:00

  • PCN119 VALIDATION OF A NEW MEASURE OF PATIENT EMPOWERMENT IN ONCOLOGY- FIVE HEALTH EDUCATION IMPACT QUESTIONNAIRE (HEIQ) SCALES

    May 1, 2011, 00:00

  • PCV34 PROPHYLAXIS USE AND 90-DAY COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENT ANALYSIS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PMS34 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS RALOXIFENE FOR TREATING OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN136 ESTIMATING UTILITIES IN CANCER- A COMPARISON OF EQ-5D AND FACT-BASED ALGORITHMS

    May 1, 2011, 00:00

  • PND23 ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE INTENSIVE CARE UNIT

    May 1, 2011, 00:00

  • PCN125 MELODY BRASIL- TREATMENT PATTERNS AND ASSOCIATED COSTS OF METASTATIC MELANOMA PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)

    May 1, 2011, 00:00

  • PGI5 COMPARISON OF HEALTH CARE UTILIZATIONS BETWEEN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE WHO SWITCHED FROM A BRANDED PROTON PUMP INHIBITOR TO A GENERIC PROTON PUMP INHIBITOR AND VICE VERSA

    May 1, 2011, 00:00

  • PMH78 PERSISTENCE OF STIMULANT TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PRS45 MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING DISCRETE EVENT SIMULATION (DES)

    May 1, 2011, 00:00

  • PSY29 A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND OXYMORPHONE LONG-ACTING ORAL TABLETS

    May 1, 2011, 00:00

  • PHP75 USE OF ELECTRONIC MEDICAL RECORDS FROM 2001 THROUGH 2010- IMPLICATIONS FOR COMPARATIVE EFFECTIVENESS RESEARCH

    May 1, 2011, 00:00

  • PMS67 FREQUENCY OF SELECT ANTI-TNF ADMINISTRATION OR RE-FILL IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PND25 ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PSY20 ECONOMIC EVALUATION OF SEQUENTIAL ANALGESIC TREATMENT IN THE MANAGEMENT OF MODERATE ANKLE SPRAIN IN MEXICAN ADULTS

    May 1, 2011, 00:00

  • PIH3 COMPARISON OF IN VITRO FERTILIZATION TRENDS AMONG INSURED PATIENTS IN MANAGED CARE IN THE UNITED STATES; COMPARISON OF STATES WITH AND WITHOUT MANDATED COMPREHENSIVE FERTILITY COVERAGE

    May 1, 2011, 00:00

  • PGI15 COST EFFECTIVENES OF THE PHARMACOLOGIC TREATMENT OF IRRITABLE BOWEL SYNDROME AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    May 1, 2011, 00:00

  • PRM47 DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS- HOW CAN BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?

    May 1, 2011, 00:00

  • PMD11 IDENTIFYING POTENTIAL DRIVERS OF COST SAVINGS WITH INSULIN ADMINISTRATION DEVICES IN TYPE-2 DIABETES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV30 A META-ANALYSIS OF RISK FACTORS TO DEVELOP CARDIOVASCULAR EVENTS AND STROKE IN SUBJECTS EXPOSED TO ENVIROMENTAL TOBACCO SMOKE

    May 1, 2011, 00:00

  • PMH64 COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA BASED ON PRODUCT LABELS WITH ACTUAL DOSAGES PRESCRIBED IN A LARGE NATIONAL DATABASE

    May 1, 2011, 00:00

  • PDB69 EXENATIDE (BID) AND LIRAGLUTIDE (QD) TREATMENT PATTERNS AMONG TYPE-2 DIABETES PATIENTS IN GERMANY

    May 1, 2011, 00:00

  • PDB56 IMPACT OF PHARMACIST MANAGEMENT ON PATIENTS WITH DIABETES ENROLLED IN A RURAL FREE CLINIC

    May 1, 2011, 00:00

  • PCN111 ANALYSIS OF HEALTH OUTCOMES IN BREAST CANCER PATIENTS USING CLUSTER ANALYSIS

    May 1, 2011, 00:00

  • PMS31 TITLE- THE RELATIVE COST-EFFECTIVENESS OF THE MOST COMMON NON-SURGICAL TREATMENTS FOR NECK PAIN

    May 1, 2011, 00:00

  • CN3 THE VALUE OF RESEARCH FOR ERCC1 TESTING IN STAGE I NON-SMALL CELL LUNG CANCER

    May 1, 2011, 00:00

  • PCN19 AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PDB8 EFFECTIVENESS AND ADHERENCE WITH FIXED-DOSE COMBINATION (FDC) VERSUS COADMINISTERED DUAL THERAPY (CDT) ANTIHYPERGLYCEMIC REGIMENS- A META-ANALYSIS

    May 1, 2011, 00:00

  • PSS7 MEDICAL CARE COSTS ASSOCIATED WITH VISION LOSS IN TAIWAN

    May 1, 2011, 00:00

  • PHP76 THE OUTLOOK OF LARGE SIMPLE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH- AN APPLICATION OF THE PRECIS FRAMEWORK

    May 1, 2011, 00:00

  • PSY51 EFFECTIVENESS OF FDA'S NEW OVER-THE-COUNTER ACETAMINOPHEN LABEL WARNING REQUIREMENTS IN IMPROVING CONSUMER RISK PERCEPTION OF LIVER DAMAGE

    May 1, 2011, 00:00

  • PHP87 IMPACT OF PRESCRIPTION MONITORING PROGRAMS ON CONTROLLED SUBSTANCE PRESCRIBING BEHAVIOR

    May 1, 2011, 00:00

  • PIH7 POTENTIALLY INAPPROPRIATE MEDICATION USE AMONG OLDER ADULTS IN THE UNITED STATES IN 2007

    May 1, 2011, 00:00

  • PMD41 SELECTING A SECONDARY DATA SOURCE FOR A LOW-VOLUME PROCEDURE IN A SPECIALTY POPULATION- A STUDY USING INPATIENT PEDIATRIC COLONOSCOPY

    May 1, 2011, 00:00

  • PHP111 OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA- IMPLICATIONS FOR NOVEL THERAPEUTICS

    May 1, 2011, 00:00

  • PSY12 BASELINE CHARACTERISTICS AND PRE–INDEX TOTAL HEALTH CARE AND RHEUMATOID ARTHRITIS-RELATED COSTS IN PATIENTS RECEIVING GOLIMUMAB THERAPY

    May 1, 2011, 00:00

  • PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

    May 1, 2011, 00:00

  • PSY39 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN KAZAKHSTAN- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PMH9 RISK OF DEATH IN DUAL ELIGIBLE NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

    May 1, 2011, 00:00

  • PCV23 COMPARING THE EFFECTIVENESS OF ROSUVASTATIN AND ATORVASTATIN IN PREVENTING CARDIOVASCULAR OUTCOMES- ESTIMATES USING THE ARCHIMEDES MODEL

    May 1, 2011, 00:00

  • PSY40 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN UKRAINE- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • OR1 THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION

    May 1, 2011, 00:00

  • PCN135 ECONOMIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER

    May 1, 2011, 00:00

  • PMD39 MINI-HTA TRENDS FOR MEDICAL DEVICES IN THE NORDICS

    May 1, 2011, 00:00

  • PMS60 PATIENT OUTCOMES ASSOCIATED WITH BIOLOGIC INFUSION SITE OF CARE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS- A CANADIAN COST EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PCN1 CHEMOTHERAPY INDUCED NAUSEA AND VOMITING EVENT RATE AMONG PATIENTS WITH CANCER TREATED WITH HIGHLY OR MODERATELY EMETOGENIC CHEMOTHERAPY AND INITIATED ON PALONOSETRON VERSUS OTHER 5-HT3-RECEPTOR ANTAGONIST ANTI-EMETIC PROPHYLAXIS IN A ...

    May 1, 2011, 00:00

  • PHP68 THE 15 YEARS EXPERIENCE OF NEW DRUGS ADOPTION AND REIMBURSEMENT IN TAIWAN'S NATIONAL HEALTH INSURANCE

    May 1, 2011, 00:00

  • SB2 ZEROS AND NON-REPORTED HEALTH CARE AND WORKPLACE PRODUCTIVITY DATA- AN APPLICATION OF TWO-STAGE ESTIMATION TECHNIQUES MEASURING INPATIENT COSTS AND ABSENTEEISM ASSOCIATED WITH LOW BACK AND NECK PAIN

    May 1, 2011, 00:00

  • PHP79 ROLE OF HTA SYSTEMS IN REIMBURSEMENT AND MARKET ACCESS- COMPARISON OF TURKEY AND POLAND

    May 1, 2011, 00:00

  • PCN87 HOW DOES PATIENT-REPORTED OUTCOME DATA INFLUENCE THE CLINICAL DECISION MAKING OF PRACTICING ONCOLOGISTS?

    May 1, 2011, 00:00

  • PSY54 APPLICATION OF THE NON-LINEAR BLINDER-OAXACA DECOMPOSITION TO STUDY RACIAL/ETHNIC DISPARITIES IN ANTI-OBESITY MEDICATION USE

    May 1, 2011, 00:00

  • PCV93 HEALTH EXPENDITURE COMPARISON OF METOPROLOL SUCCINATE VS METOPROLOL TARTARATE

    May 1, 2011, 00:00

  • PRM43 BIOSIMILARS- DEMONSTRATING SIMILARITY THROUGH EVIDENCE

    May 1, 2011, 00:00

  • CO1 COMPARATIVE EFFECTIVENESS ANALYSIS OF TNF BLOCKERS IN RHEUMATOID ARTHRITIS (RA) PATIENTS IN A REAL-WORLD SETTING

    May 1, 2011, 00:00

  • PCV106 RE-HOSPITALIZATION RATES OF ACUTE CORONARY SYNDROME PATIENTS IN REAL WORLD CLINICAL PRACTICE- OBSERVATIONS FROM A NATIONAL ADMINISTRATIVE CLAIMS DATA

    May 1, 2011, 00:00

  • PMH84 PERFORMANCE OF TWO INSTRUMENTAL VARIABLES TO EXAMINE THE RISK OF DEATH IN DUAL ELIGIBLE ELDERLY NURSING HOME RESIDENTS USING ANTIPSYCHOTIC AGENTS

    May 1, 2011, 00:00

  • PRS8 DISEASE PROGRESSION IN CYSTIC FIBROSIS — SYNTHESIS OF SURVIVAL EVIDENCE

    May 1, 2011, 00:00

  • PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE- ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY

    May 1, 2011, 00:00

  • PRS13 ECONOMIC CONSEQUENSES OF USING TULATHROMYCIN, FLORFENICOL, AND TILMICOSIN FOR TREATMENT OF CATTLE AT HIGH RISK OF DEVELOPING BOVINE RESPIRATORY DISEASE IN UNITED STATES FEEDLOTS

    May 1, 2011, 00:00

  • PRS39 EFFECT OF BIOMASS SMOKE ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN RURAL LOCALITIES OF COLOMBIA

    May 1, 2011, 00:00

  • PCN118 PREDICTING THE FUTURE IMPACT OF EMERGING TECHNOLOGIES ON HEPATOCELLULAR CARCINOMA (HCC)- MEASURING STAKEHOLDERS PREFERENCES WITH BEST-WORST SCALING

    May 1, 2011, 00:00

  • PDB66 COSTS OF THE PHARMACEUTICAL PROGRAM TO TREAT T2DM PATIENTS FROM HIPERDIA- GOVERNMENT HEALTH CARE PROGRAM FOR DIABETES AND HYPERTENSION POPULATION UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PHP22 ASSOCIATION OF SELF-REPORTED HEALTH STATUS WITH COST-RELATED MEDICATION NONADHERENCE AND OUT-OF-POCKET PHARMACY SPENDING AMONG SENIOR MEDICARE BENEFICIARIES

    May 1, 2011, 00:00

  • PMS70 A COMPARISON OF NON-RESPONDER IMPUTATION AND LAST-OBSERVATION-CARRIED-FORWARD ANALYSIS METHODS IN RHEUMATOID ARTHRITIS CLINICAL TRIALS

    May 1, 2011, 00:00

  • PHP4 WHEN STAKEHOLDERS DON'T AGREE- DISCREPANCIES IN MAB “APPROVALS” OVER THE PAST TEN YEARS

    May 1, 2011, 00:00

  • CN2 ESTIMATED EFFECTS OF THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM ON CERVICAL CANCER MORTALITY

    May 1, 2011, 00:00

  • PIN25 COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF THE VARICELLA VACCINE IN COLOMBIA

    May 1, 2011, 00:00

  • PIH19 COSTS AND EFFECTS OF A MULTIFACETED INTERVENTION TO IMPROVE THE QUALITY OF CARE OF CHILDREN IN DISTRICT HOSPITALS IN KENYA

    May 1, 2011, 00:00

  • PSU14 HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS ON KIDNEY TRANSPLANT WAITING LIST - WHAT FACTORS REALLY MATTER?

    May 1, 2011, 00:00

  • PDB75 THE IMPACT OF HOSPITAL DAYS ON CALCULATION OF PDC FOR DIABETES MEDICATIONS

    May 1, 2011, 00:00

  • PMH53 ASSESSING THE IMPACT OF MAJOR DEPRESSIVE DISORDER (MDD) ON FAMILY FUNCTIONING- DEVELOPMENT OF THE DEPRESSION AND FAMILY FUNCTIONING SCALE

    May 1, 2011, 00:00

  • PSY22 ANALYSING THE BENEFITS AND COST SAVING OF ORAL VERSUS IV FLUDARABINE FOR MANAGEMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

    May 1, 2011, 00:00

  • PIH5 RISK OF HIP AND SUBTROCHANTERIC OR DIAPHYSEAL FEMORAL FRACTURES IN ALENDRONATE USERS

    May 1, 2011, 00:00

  • PMS49 ADOPTION, CHOICE, AND UTILIZATION OF BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS IN THE MEDICARE POPULATION

    May 1, 2011, 00:00

  • PSY37 THE PAIN MANAGEMENT IS ALWAYS A PUBLIC HEALTH CHALLENGE

    May 1, 2011, 00:00

  • PIN52 MAPPING STATE AND FEDERAL IMMUNIZATION RECORDS POLICIES

    May 1, 2011, 00:00

  • PIH22 PRIMARY MEDICATION NONADHERENCE- A RETROSPECTIVE ANALYSIS OF ELECTRONIC PRESCRIPTIONS IN AN INTEGRATED HEALTHCARE SETTING

    May 1, 2011, 00:00

  • PHP20 MEDICATION USE SURVEY OF INPATIENTS WITH BASIC MEDICAL INSURANCE (2010)

    May 1, 2011, 00:00

  • PCN123 A SYSTEMATIC REVIEW OF TREATMENT GUIDELINES FOR METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PMS22 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

    May 1, 2011, 00:00

  • PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)- A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY

    May 1, 2011, 00:00

  • PUK14 A MARKOV MODEL COMPARING SACRAL NEUROMODULATION AND BOTULINUM TOXIN-A FOR MEDICARE PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER REFRACTORY TO CONSERVATIVE CARE

    May 1, 2011, 00:00

  • PCV60 MEDICATION ADHERENCE, PERSISTENCE, AND HEALTH CARE COSTS FOR PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION

    May 1, 2011, 00:00

  • PCV46 LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY

    May 1, 2011, 00:00

  • PDB34 PHARMACOECONOMIC EVALUATION OF A PHARMACIST-MANAGED DIABETES CLINIC

    May 1, 2011, 00:00

  • PHP33 IMPACT OF PHARMACY AND MEDICAL PLAN INTEGRATION ON OVERALL MEDICAL COSTS

    May 1, 2011, 00:00

  • PMH15 IMPACT OF ADHERENCE TO FIRST THERAPY ON THE RISK OF ANTIDEPRESSANT SWITCHING

    May 1, 2011, 00:00

  • PCN34 LONG-TERM DIRECT MEDICAL COSTS IN PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA WHO RECEIVE FRONTLINE CHEMOTHERAPY WITH VERSUS WITHOUT RITUXIMAB - A SEER MEDICARE ANALYSIS

    May 1, 2011, 00:00

  • PCN64 ECONOMIC EVALUATION OF THREE FORMULATIONS OF LEUPROLIDE ACETATE IN ANDROGEN DEPRIVATION THERAPY FOR ADVANCED PROSTATE CANCER IN BELGIUM

    May 1, 2011, 00:00

  • PGI4 PREDICTORS OF HEPATITIS C TREATMENT INITIATION

    May 1, 2011, 00:00

  • PMS50 PATTERNS OF TREATMENT UTILIZATION FOR OSTEOPOROSIS IN ELDERLY WOMEN RESIDING IN THE COMMUNITY AND IN LONG-TERM CARE FACILITIES

    May 1, 2011, 00:00

  • PMS62 ASSOCIATION OF SATISFACTION WITH SUBCUTANEOUS ANTI-TNF THERAPY AND CLINICAL OUTCOMES, HEALTH STATUS, AND LOST WORK PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PCN127 METHODS FOR INDIRECT COMPARISON OF EFFECTIVENESS IN COST-EFFECTIVENESS ANALYSES OF ONCOLOGY AGENTS- THE PROPORTIONAL HAZARDS ASSUMPTION MATTERS

    May 1, 2011, 00:00

  • PCN86 A Q-TWIST ANALYSIS COMPARING PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) WITH BSC ALONE IN PATIENTS WITH WILD-TYPE KRAS METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PMH14 CLINICAL EFFECTIVENESS ANALYSIS OF NALTREXONE VERSUS ACAMPROSATE AND PLACEBO IN ALCOHOL DEPENDENT PATIENTS TREATED WITH PSYCHOTHERAPY

    May 1, 2011, 00:00

  • PCN115 A CROSS-COUNTRY COMPARISON OF SECOND-LINE MULTIPLE MYELOMA TREATMENTS

    May 1, 2011, 00:00

  • PCN105 ESTIMATING NICE'S COST EFFECTIVE THRESHOLD FOR END-OF-LIFE CANCER TREATMENTS

    May 1, 2011, 00:00

  • PHP35 DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT- THE GOOD, THE BAD, AND THE FUTURE

    May 1, 2011, 00:00

  • PMS18 IMPACT OF TREATMENT PERSISTENCE AND COMPLIANCE ON HEALTH CARE RESOURCE UTILISATION AND TOTAL HEALTH CARE COST IN POST MENOPAUSAL WOMEN PRESCRIBED ORAL BISPHOSPHONATES – A RETROSPECTIVE STUDY USING THE GENERAL PRACTICE RESEARCH DATABAS ...

    May 1, 2011, 00:00

  • PCV12 IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS (DDIS) ON HEALTH OUTCOMES AND COST TO MEDICAID- THE MONETARY BENFITS OF QUALITY HEALTH CARE

    May 1, 2011, 00:00

  • PMH59 DIFFERENCES IN BASELINE PROBLEM SEVERITY BETWEEN PRESCRIPTION AND STREET OPIOID ABUSERS AMELIORATED AFTER PARTICIPATION IN DISEASE MANAGEMENT PROGRAM- RESULTS AT ONE YEAR

    May 1, 2011, 00:00

  • PSU9 ECONOMIC EVALUATION OF THE CURRENT TREND TOWARDS MORE UNCEMENTED FIXATION IN PRIMARY HIP ARTHROPLASTIES AND THE POTENTIAL IMPACT OF CHANGES OF THE DEVELOPMENT IN ENGLAND AND WALES

    May 1, 2011, 00:00

  • PMH52 PATIENT AND PHYSICIAN PREFERENCES AND SATISFACTION WITH ORAL AND LONG-ACTING INJECTABLE LONG-TERM ANTIPSYCHOTIC TREATMENT FOR PSHYCHOTIC DISORDERS

    May 1, 2011, 00:00

  • PSY65 CHARACTERISTICS OF GOLIMUMAB UTILIZATION IN A LARGE NATIONAL PAYER DATABASE

    May 1, 2011, 00:00

  • PRM16 VALIDATION AND PSYCHOMETRIC EVALUATION OF A 5-ITEM MEASURE OF PERCEIVED SOCIAL SUPPORT

    May 1, 2011, 00:00

  • PSY55 NATIONAL TRENDS IN ANTI-OBESITY MEDICATION USE FROM 2002 TO 2007

    May 1, 2011, 00:00

  • PHP13 THE IMPACT OF A QUALITY IMPROVEMENT INITIATIVE ON INAPPROPRIATE MEDICATION USE IN THE OUTPATIENT ELDERLY

    May 1, 2011, 00:00

  • PIH30 POSTPARTUM DEPRESSION IN VULNERABLE PEOPLE IN SOUTH KOREA

    May 1, 2011, 00:00

  • PDB30 A CROSS-SECTIONAL SURVEY ON ECONOMIC BURDEN OF TYPE-2 DIABETES MELLITUS PATIENTS WITH ORAL ANTI-DIABETIC DRUGS THERAPY IN CHINA

    May 1, 2011, 00:00

  • EV2 PAYERS AND PROS- BEYOND QOL

    May 1, 2011, 00:00

  • PDB46 DEVELOPMENT OF THE DIABETIC PERIPHERAL NEUROPATHIC PAIN IMPACT MEASURE- A PATIENT-REPORTED OUTCOME MEASURE OF THE IMPACT OF DPNP ON FUNCTIONING

    May 1, 2011, 00:00

  • PSY7 A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY INFORMATION ON RECOMBINANT FACTOR VIIA (RFVIIA) IN THE RARE DISORDER ACQUIRED HEMOPHILIA- THE ACQUIRED HEMOPHILIA SURVEILLANCE (AHS) PROJECT

    May 1, 2011, 00:00

  • PIN14 ECONOMIC BURDEN OF SEVERE SEPSIS IN A VERTICALLY INTEGRATED HEALTH CARE SYSTEM (IHS)

    May 1, 2011, 00:00

  • PIH17 COST-EFFECTIVENESS OF ABLE A FUNCTIONAL PROGRAM TO DECREASE MORTALITY IN COMMUNITY-DWELLING OLDER ADULTS

    May 1, 2011, 00:00

  • PND52 HEALTH CARE RESOURCE UTILIZATION BEFORE AND AFTER INITIATION OF ARMODAFINIL TREATMENT FOR WAKEFULNESS

    May 1, 2011, 00:00

  • PHP86 IRRATIONAL USE OF ANTIBIOTICS AND ROLE OF PHARMACISTS- AN INSIGHT FROM A QUALITATIVE STUDY IN NEW DELHI, INDIA

    May 1, 2011, 00:00

  • PRM36 NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS RATIO ACCOUNTING FOR SKEWNESS

    May 1, 2011, 00:00

  • PCN75 ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB

    May 1, 2011, 00:00

  • PHP8 PHYSICIAN SHORTAGE IMPACT ON PATIENT RX USE FOR SELECT CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PMH73 RETROSPECTIVE ANALYSIS OF THE IMPACT OF PERSISTENCE ON HEALTH CARE CHARGES AMONG OPIOID-DEPENDENT PATIENTS TREATED WITH BUPRENORPHINE/NALOXONE USING AN INSURANCE DATABASE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSY3 OPIOIDS IN NON-MALIGNANT PAIN- ARE THEY EQUIVALENT IN SAFETY PROFILE? A NETWORK META-ANALYSIS

    May 1, 2011, 00:00

  • PHP50 MIXED EVIDENCE FOR THE ”HEALTHY ADHERER EFFECT” IN A SAMPLE OF 22,070 ADULTS WITH CHRONIC DISEASE IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS5 PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE

    May 1, 2011, 00:00

  • PSU18 IMPACT OF HEALTH INSURANCE ON RECEIVING BREAST CONSERVING SURGERY WITH RADIATION IN FLORIDA

    May 1, 2011, 00:00

  • PSY77 COMPARISON OF OBESITY-ASSOCIATED COMORBIDITIES BETWEEN EMR AND CLAIMS DATABASES

    May 1, 2011, 00:00

  • PIN22 COST-EFFECTIVENESS OF A CATCH-UP DOSE OF HEPATITIS B VACCINE IN COLOMBIAN ADOLESCENTS

    May 1, 2011, 00:00

  • PMH13 COMPARATIVE EFFECTIVENESS STUDY OF RISPERIDONE LONG-ACTING INJECTABLE- THE USE OF DYNAMIC EXPOSURE METHODOLOGY FOR RISK SHARING AGREEMENT

    May 1, 2011, 00:00

  • PCN16 MAJOR CHANGES IN CHEMOTHERAPY REGIMENS ADMINISTERED TO BREAST CANCER PATIENTS DURING 2000-2008

    May 1, 2011, 00:00

  • PCV16 MANAGING GROWING POPULATION OF TYPE-2 DIABETES FROM COMMUNITY TO TEACHING HOSPITALS IN CHINA

    May 1, 2011, 00:00

  • PSY8 DIRECT AND INDIRECT COSTS OF PRIVATELY-INSURED PATIENTS TREATED WITH OXYMORPHONE EXTENDED-RELEASE OR OXYCODONE CONTROLLED-RELEASE TABLETS

    May 1, 2011, 00:00

  • PCV75 EFFECT OF ACEI AND ARB ON HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERTENSION AND DIABETES

    May 1, 2011, 00:00

  • PDB15 SHORT-TERM ASSOCIATION OF ANTIDEPRESSANT DRUG USE, LIFE-STYLE RISK FACTORS AND NEW-ONSET DIABETES

    May 1, 2011, 00:00

  • PCV33 USE OF SECONDARY DATA SOURCES TO ESTIMATE INPATIENT COSTS AND PAYMENTS FOR ACUTE CORONARY SYNDROME

    May 1, 2011, 00:00

  • MD2 PRESCRIPTION DRUG COST AND USE IN THE MEDICARE PART D POPULATION - USES OF A NEW LIMITED DATA SET

    May 1, 2011, 00:00

  • PRS32 HOSPITAL COST VERSUS MEDICARE PAYMENT FOR RESPIRATORY INSUFFICIENCY, ARREST AND FAILURE

    May 1, 2011, 00:00

  • PMS37 INDIRECT COMPARISON OF ADALIMUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIATIC ARTHRITIS

    May 1, 2011, 00:00

  • PCV68 FACTORS ASSOCIATED WITH NON-ADMINISTRATION OF ORDERED PHARMACOLOGIC VENOUS THROMBOEMBOLISM PROPHYLAXIS DOSES

    May 1, 2011, 00:00

  • PCN128 LINKING MEDICARE, MEDICAID AND CANCER REGISTRY DATA TO STUDY BURDEN OF CANCERS IN WEST VIRGINIA (FUNDING- AHRQ - R24 HS018622-01)

    May 1, 2011, 00:00

  • IN2 ASSOCIATION BETWEEN DRUG TOLERABILITY AND ECONOMIC IMPACT FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT

    May 1, 2011, 00:00

  • PHP71 IMPACT OF THE MEDICARE PART D COVERAGE GAP ON PRESCRIPTION DRUG UTILIZATION AND MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PSY5 AN INVESTIGATION INTO THE RELATIONSHIP BETWEEN OBESITY AND SKIN AND SOFT TISSUE INFECTIONS REQUIRING HOSPITALIZATION

    May 1, 2011, 00:00

  • PIN35 CLINICAL EFFECTIVENESS AND COST UTILITY OF ENTECAVIR VERSUS LAMIVUDINE AND ADEFOVIR IN CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PIN10 ECOMOMIC EVALUATION OF DAPTOMYCIN COMPARE WITH STANDARD THERAPY IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA WITH OR WITHOUT ENDOCARDITIS IN COLOMBIA

    May 1, 2011, 00:00

  • PCV69 IMPACT OF COMMUNITY PHARMACIST-LED COUNSELING ON IMPROVING MEDICATION ADHRERENCE

    May 1, 2011, 00:00

  • PGI18 FEASIBILITY OF ASSESSING UTILITY BY EQ-5D AND TIME-TRADE-OFF METHODS IN TAIWANESE CHRONIC HEPATITIS B PATIENTS

    May 1, 2011, 00:00

  • PUK18 THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL)- DEVELOPMENT OF A CONCEPTUAL FRAMEWORK

    May 1, 2011, 00:00

  • PMH76 PHARMACIST AND PHARMACY STAFF KNOWLEDGE AND ATTITUDES TOWARDS SUICIDE AND SUICIDE PREVENTION AFTER A NATIONAL VA TRAINING PROGRAM

    May 1, 2011, 00:00

  • PCN137 COMPREHENSIVE REVIEW OF MANAGEMENT EFFICIENCY STRATEGIES AMONG ONCOLOGY PRACTICES- EXISTING EVIDENCE AND OPPORTUNITIES FOR FUTURE RESEARCH

    May 1, 2011, 00:00

  • DM3 IMPACT OF MONTHLY PRESCRIPTION CAP ON MEDICATION PERSISTENCY AMONG PATIENTS WITH DIABETES, HYPERTENSION, OR HYPERLIPIDEMIA

    May 1, 2011, 00:00

  • PCN82 IMPACT OF OPTIMAL CML RESPONSE ON PATIENT SATISFACTION AND QUALITY OF LIFE- A PATIENT SURVEY FROM THE ASSOCIATION OF CANCER ONLINE RESOURCES (ACOR) DATABASE

    May 1, 2011, 00:00

  • PDB74 BETA-VERIFICATION OF A DIABETES MODELING FRAMEWORK AGAINST PUBLISHED COHORT TRIALS

    May 1, 2011, 00:00

  • PRM23 MEASURING THE IMPACT OF PREVIOUS TREATMENT CYCLES ON HEALTH UTILITY IN PATIENTS RECEIVING BOTULINUM TOXIN TYPE A (BONTA) IN A PROSPECTIVE OBSERVATIONAL COHORT STUDY- MOBILITY STUDY

    May 1, 2011, 00:00

  • PMD31 IMPACT OF GASTRIC ELECTRIC STIMULATION ON HEALTH STATE UTILITIES OF DIABETIC GASTROPARESIS PATIENTS- RESULTS FROM A PROSPECTIVE CLINICAL TRIAL

    May 1, 2011, 00:00

  • PDB19 ECONOMIC ASSESSMENT OF CONVERSION TO INSULIN PEN DEVICES IN A LONG TERM CARE FACILITY CHAIN

    May 1, 2011, 00:00

  • PGI23 WORK PRODUCTIVITY AMONG GENOTYPE 1 HEPATITIS C VIRUS (HCV) TREATMENT-NAÏVE PATIENTS RECEIVING TELAPREVIR-BASED TREATMENT REGIMENS- RESULTS FROM ADVANCE AND ILLUMINATE STUDIES

    May 1, 2011, 00:00

  • PCN38 FIRST-YEAR COSTS FOR THE 19 MOST COMMON CANCER DIAGNOSES IN ONTARIO

    May 1, 2011, 00:00

  • PSY48 A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA)

    May 1, 2011, 00:00

  • PMH83 ESTIMATING SAMPLE SIZE FOR PSYCHOMETRIC STUDIES USING CONFIRMATORY FACTOR ANALYSIS

    May 1, 2011, 00:00

  • PDB62 RELATIONSHIP BETWEEN SOCIAL AND ECONOMIC FACTORS AND ANTIDIABETIC MEDICATION PRESCRIBING PATTERNS

    May 1, 2011, 00:00

  • PRS42 CONCOMITANT ASTHMA MEDICATION USE IN PATIENTS USING OMALIZUMAB- RESULTS FROM THREE LARGE INSURANCE CLAIMS DATABASES

    May 1, 2011, 00:00

  • PCN18 AN EPIDEMIOLOGICAL MODEL OF PROSTATE CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • CE3 COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ASSESSMENT- A GRAPHICAL WAY TO COMBINE THE TWO FOR THE AID OF DECISION-MAKERS

    May 1, 2011, 00:00

  • PMS39 MOST EFFECTIVE ADHERENCE-ENHANCING INTERVENTIONS FOR OSTEOPOROSIS MEDICATIONS

    May 1, 2011, 00:00

  • PMH35 COMPARISONS OF MENTAL HEALTH-RELATED MEDICAL CARE UTILIZATION AND COSTS FOLLOWING THE INITIATION OF ORAL VERSUS LONG-ACTING INJECTABLE RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PND14 BURDEN OF ILLNESS IN THE UNITED STATES FOR ADULT EPILEPSY PATIENTS WITH PARTIAL ONSET SEIZURES RECEIVING ANTI-EPILEPTIC DRUGS

    May 1, 2011, 00:00

  • PMH48 AMBER TODD

    May 1, 2011, 00:00

  • PDB20 BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF SAXAGLIPTIN IN THE TREATMENT OF TYPE-2 DIABETES IN CHILE

    May 1, 2011, 00:00

  • CE1 COST-EFFECTIVENESS SENSITIVITY ANALYSIS METHODS- A COMPARISON OF ONE-WAY SENSITIVITY, ANALYSIS OF COVARIANCE, AND EXPECTED VALUE OF PARTIAL PERFECT INFORMATION

    May 1, 2011, 00:00

  • PIN24 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB AMONG PRETERM INFANTS COVERED BY MEDICAID IN THE UNITED STATES

    May 1, 2011, 00:00

  • PDB60 EFFECT OF MEDICARE PART D COVERAGE GAP ON MEDICATION CONSUMPTION BEHAVIORS- CASE OF ORAL ANTI-DIABETIC MEDICATIONS

    May 1, 2011, 00:00

  • PUK11 UPDATED ECONOMIC ANALYSIS OF FESOTERODINE RELATIVE TO TOLTERODINE AND SOLIFENACIN FOR THE TREATMENT OF OVERACTIVE BLADDER- THE SWEDISH PERSPECTIVE

    May 1, 2011, 00:00

  • PHP30 CAN PRICING SCHEMES IMPROVE MARKET ACCESS FOR INNOVATIVE HIGH PRICED DRUGS?

    May 1, 2011, 00:00

  • PHP97 PRO LABEL CLAIMS- AN ANALYSIS BASED ON A REVIEW OF PROS AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010

    May 1, 2011, 00:00

  • PSU22 A PATIENT-BASED QUESTIONANIRE TO ASSESS OUTCOMES OF FOOT SURGERY- VALIDATION IN THE CONTEXT OF SURGERY FOR HALLUX VALGUS

    May 1, 2011, 00:00

  • PCV48 COST-EFFECTIVENESS ANALYSIS OF ANTIARRHYTHMIC THERAPIES FOR THE TREATMENT OF SUPRAVENTRICULAR TACHYCARDIA AND SURGICALLY INDUCED TACHYCARDIAS AND HYPERTENSION

    May 1, 2011, 00:00

  • IN1 MEASUREMENT OF SYMPTOMS AND IMPACT OF INFLUENZA- DEVELOPMENT OF THE SYMPTOM INTENSITY AND IMPACT OF INFLUENZA QUESTIONNAIRE (FLU-IIQ)

    May 1, 2011, 00:00

  • PMD18 THE COST-EFFECTIVENESS OF INITIATING SENSOR-AUGMENTED PUMP THERAPY VERSUS MULTIPLE DAILY INJECTIONS OF INSULIN IN ADULTS WITH TYPE 1 DIABETES- EVALUATING A TECHNOLOGY IN EVOLUTION

    May 1, 2011, 00:00

  • PDB42 ADHERENCE TO ROUTINE OR STRUCTURED GLUCOSE MONITORING- A QUALITATIVE EVALUATION FROM THE STEP STUDY

    May 1, 2011, 00:00

  • PCV18 MEDICATION ADHERENCE AND HOSPITALIZATION AMONG CHRONIC HEART FAILURE MEDICARE BENEFICIARIES WITH AND WITHOUT DEPRESSION

    May 1, 2011, 00:00

  • PMS20 HEALTH CARE RESOURCES UTILIZATION IN THE MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS- ANALYSES WITH THE RAMQ DATABASE

    May 1, 2011, 00:00

  • PIN41 INFLUENZA VACCINATION RATES AMONG HIGH RISK GROUPS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PND17 IMPACT OF WALKING AND MOBILITY PROBLEMS ON REQUIREMENT FOR HEALTHCARE AMONG MULTIPLE SCLEROSIS PATIENTS

    May 1, 2011, 00:00

  • PMH23 COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH AND WITHOUT MEDICATION FOR OPIOID DEPENDENCY

    May 1, 2011, 00:00

  • PRM21 CONVERTING PAPER VERSIONS OF PATIENT REPORTED OUTCOME INSTRUMENTS TO ELECTRONIC VERSIONS- IDENTIFYING THE REQUIRED STEPS

    May 1, 2011, 00:00

  • PRM2 MEASURING DRUG THERAPY GUIDELINES ON OUTCOMES- A TUTORIAL

    May 1, 2011, 00:00

  • DS4 BURDEN OF PROOF…PROOF OF PRINCIPLE- REPLICATION QUANTIFICATION, REPLICATION AND VALIDATION… STANDARDS OF EVIDENCE IN OUTCOMES RESEARCH SURROGATE ENDPOINTS FOR ALL-CAUSE MORTALITY

    May 1, 2011, 00:00

  • PCN72 GENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER- A COST-EFFECTIVENESS ANALYSIS OF 1000 STRATEGIES FOR THE PROVISION OF ADJUVANT! ONLINE, ONCOTYPE DX AND CHEMOTHERAPY

    May 1, 2011, 00:00

  • PND34 MAPPING THE INSOMNIA SEVERITY INDEX (ISI) TO THE EQ-5D UTILITIES

    May 1, 2011, 00:00

  • PSY18 A DECISION ANALYSIS MODEL EXPLORING THE RESULTS OF A PHASE II TRIAL OF ELTROMBOPAG FOR PATIENTS WITH CHRONIC HEPATITIS C, CIRRHOSIS AND THROMBOCYTOPENIA

    May 1, 2011, 00:00

  • PMD6 READMISSION RATES AND COSTS ASSOCIATED WITH FIBRIN SEALANT USE AMONG PATIENTS UNDERGOING ORTHOPEDIC SURGERY

    May 1, 2011, 00:00

  • PDB28 COST SAVINGS IN TYPE-2 DIABETES (T2D) WITH INSULIN GLARGINE COMPARED WITH INSULIN DETEMIR IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PMS43 QUALITY OF LIFE AND FIBROMYALGIA - A SYSTEMATIC LITERATURE REVIEW

    May 1, 2011, 00:00

  • PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

    May 1, 2011, 00:00

  • PHP81 CAREGIVER WELL-BEING AND HEALTH CARE ACCESS AND QUALITY AMONG CHILDREN WITH CHRONIC PHYSICAL AND MENTAL CONDITIONS

    May 1, 2011, 00:00

  • QA1 COST-EFFECTIVENESS OF DUTASTERIDE AS A CHEMOPREVENTION IN PROSTATE CANCER- REDUCE WITHIN-TRIAL ANALYSIS

    May 1, 2011, 00:00

  • PSY14 ECONOMIC IMPACT OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS TAKING OPIOID ANALGESICS

    May 1, 2011, 00:00

  • PIH11 COST ANALYSIS OF TOTAL PARENTERAL NUTRITION IN THE NEONATAL AND PEDIATRIC CARE IN BELGIAN HOSPITALS

    May 1, 2011, 00:00

  • PND8 INCIDENCE RATES OF SUBARACHNOID HEMORRHAGE IN PATIENTS WITH UNRUPTURED ANEURYSM IN SOUTH KOREA FROM 2006-2009

    May 1, 2011, 00:00

  • PIH38 EPIDEMIOLOGY OF ADOLESCENT AND YOUNG ADULT HOSPITAL UTILIZATION FOR ALCOHOL AND DRUG USE, SUICIDE, AND POISONING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIH39 THE EFFECT OF ELECTRONIC-MEDICAL-RECORD SYSTEM SOPHISTICATION ON PREVENTIVE HEALTH CARE FOR WOMEN

    May 1, 2011, 00:00

  • PMH62 TREND IN UTILIZATION OF AND SPENDING ON BENZODIAZEPINES IN THE UNITED STATES MEDICAID PROGRAM- 1991-2009

    May 1, 2011, 00:00

  • PRM30 RESULTS FROM A NEW VISUAL ANALOGUE SCALE PROTOCOL FOR EQ-5D VALUATIONS

    May 1, 2011, 00:00

  • PRM8 LEGAL RESTRICTIONS ON THE USE OF QALYS IN PHARMACOECONOMIC ANALYSIS IN GERMANY

    May 1, 2011, 00:00

  • PCV81 SUSTAINING CLINICAL OUTCOMES OVER 24 MONTHS- IS MEDICATION THERAPY MANAGEMENT (MTM) THE ANSWER?

    May 1, 2011, 00:00

  • PMD34 PREFERENCES FOR GENETIC TESTING TO ASSESS COLON-CANCER RISKS

    May 1, 2011, 00:00

  • PMH67 CO-PRESCRIBING CHOLINESTERASE INHIBITORS WITH ANTICHOLINERGIC URINARY INCONTINENCE MEDICATIONS

    May 1, 2011, 00:00

  • SB3 INNOVATIVE DESIGN FOR A COMPARATIVE EFFECTIVENESS STUDY OF SCHIZOPHRENIA TREATMENTS- ANALYSIS OF RECORD REVIEW DATA INCORPORATING RANDOMIZATION AND PROPENSITY SCORE MATCHING

    May 1, 2011, 00:00

  • PRM4 WHAT IS IMPORTANT DURING THE PHARMACOECONOMIC EVALUATION OF CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)?—A SURVEY RESEARCH

    May 1, 2011, 00:00

  • PMH43 ECONOMIC IMPACT OF CYP450 PHARMACOGENETIC TESTING ON DEPRESSION TREATMENT

    May 1, 2011, 00:00

  • PHP9 IMPACT OF FREE PRESCRIPTIONS IN WALES ON PRESCRIBING - A THIN DATABASE STUDY

    May 1, 2011, 00:00

  • PCN102 SYNCHRONIZATION OF ADMINISTRATIONS OF CHEMOTHERAPY AND ERYTHROPOIESIS-STIMULATING AGENTS AND FREQUENCY OF ASSOCIATED HEALTH CARE VISITS

    May 1, 2011, 00:00

  • PCV52 COST-EFFECTIVNESS STUDY OF CITICOLINE IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN RUSSIA

    May 1, 2011, 00:00

  • PMS26 COST-EFFECTIVENESS MODELING IN OSTEOPOROSIS- A SYSTEMATIC LITERATURE REVIEW AND OVERVIEW

    May 1, 2011, 00:00

  • PCV10 THE EFFECT OF INTERACTIONS BETWEEN CLOPIDOGREL AND PROTON PUMP INHIBITORS ON ADVERSE CARDIOVASCULAR OUTCOMES IN COMMERCIALLY INSURED PATIENTS WITH ACUTE CORONARY SYNDROME

    May 1, 2011, 00:00

  • PDB2 EVALUATING ONE-YEAR STABILITY OF THE TOTAL ILLNESS BURDEN INDEX

    May 1, 2011, 00:00

  • PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM

    May 1, 2011, 00:00

  • PMH81 RELATIONSHIP BETWEEN ADHERENCE TO ANTIDEPRESSANT TREATMENTS AND DEPRESSIVE RELAPSE

    May 1, 2011, 00:00

  • PIN43 UTILIZATION AND SPENDING OF ANTIFUNGAL AGENTS IN THE UNITED STATES OUTPATIENT MEDICAID POPULATION- 1991-2009

    May 1, 2011, 00:00

  • OR3 THE DIRECT AND INDIRECT COSTS ASSOCIATED WITH HYPOGONADISM AMONG PRIVATELY-INSURED EMPLOYEES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS45 WILLINGNESS TO PAY FOR OSTEOPOROSIS TREATMENT TO PREVENT FRACTURE IN KOREAN POPULATION

    May 1, 2011, 00:00

  • PRM7 DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED STATES- THE INFLUENCE OF DRUG INTENDED OUTCOMES OF DRUG PRICING

    May 1, 2011, 00:00

  • PSS29 DEVELOPMENT OF THE MODIFIED OCULAR COMFORT INDEX (MOCI)

    May 1, 2011, 00:00

  • PCV71 EVALUATING MEDICATION ADHERENCE WITH CHRONIC CARDIOVASCULAR THERAPIES AMONG UNINSURED WORKING ADULTS- RESULTS FROM THE TEXAS DEMONSTRATION TO MAINTAIN INDEPENDENCE AND EMPLOYMENT (DMIE) STUDY

    May 1, 2011, 00:00

  • PSS19 PSYCHOMETRIC EVALUATION OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE 25 AND VISUAL FUNCTION QUESTIONNAIRE UTILITY INDEX IN PATIENTS WITH NON-INFECTIOUS INTERMEDIATE AND POSTERIOR UVEITIS

    May 1, 2011, 00:00

  • PDB9 IMPACT OF EXENATIDE, PEN INSULIN AND VIAL/SYRINGE INSULIN ON PATIENT OUTCOMES IN A DIABETES POPULATION IN THE UNITED STATES- A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE AND FIRST-YEAR COSTS

    May 1, 2011, 00:00

  • PSU2 USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY POTENTIAL PREDICTORS FOR BARIATRIC SURGERY SUCCESS

    May 1, 2011, 00:00

  • PHP77 THE STATE OF HEALTH ECONOMICS AND PHARMACOECONOMICS RESEARCH IN RUSSIA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PGI14 PERCEIVED VALUE ASSESSMENT OF ENTECAVIR VERSUS TENOFOVIR IN CHRONIC HEPATITIS B

    May 1, 2011, 00:00

  • PSY15 COSTS OF CARE FOR PRIVATELY INSURED MALES WITH HEMOPHILIA IN THE UNITED STATES, 2008

    May 1, 2011, 00:00

  • PDB33 EVALUATING THE COST-EFFECTIVENESS OF SWITCHING FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING- A MODELING STUDY BASED ON THE PREDICTIVE STUDY

    May 1, 2011, 00:00

  • PSU25 IDENTIFYING IMPROVEMENT OF PRESSURE ULCER PREVENTION AT THE POINT-OF-CARE WITH MULTIPLE METHODS IN THE DEPARTMENT OF SURGERY

    May 1, 2011, 00:00

  • PCV61 THE IMPACT OF THE MEDICARE DOUGHNUT HOLE ON MEDICATION USE BEHAVIORS AND HEALTH CARE RESOURCE UTILIZATION AMONG BENEFICIARIES TAKING STATIN MEDICATION

    May 1, 2011, 00:00

  • PSY17 A PHARMACOECONOMIC EVALUATION OF ROMIPLOSTIM (NPLATE®) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN MEXICO

    May 1, 2011, 00:00

  • EE4 BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A LARGE COMPARISON COHORT

    May 1, 2011, 00:00

  • PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT

    May 1, 2011, 00:00

  • PRM41 IS IT TIME TO ELIMINATE THE ICER? USING NET BENEFITS TO REPORT THE RESULTS OF DETERMINISTIC COST-EFFECTIVENESS ANALYSES

    May 1, 2011, 00:00

  • PCV111 IDENTIFICATION OF RESPONSE SHIFT AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE USING TWO STRUCTURAL EQUATION MODELING TECHNIQUES

    May 1, 2011, 00:00

  • PDB52 A LITERATURE REVIEW OF DIABETES RISK ASSESSMENT TOOLS

    May 1, 2011, 00:00

  • PIN31 COST-EFFECTIVENESS ANALYSIS OF DIFFERENT APPROACHES TO THE DIAGNOSIS AND TREATMENT OF INFLUENZA-LIKE ILLNESS IN HEALTHY ADULTS

    May 1, 2011, 00:00

  • PCN30 DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS

    May 1, 2011, 00:00

  • PSY9 HEALTH CONSEQUENCES AND COSTS OF TACHOSIL® AS HAEMOSTATIC TREATMENT IN LIVER SURGERY VERSUS TISSUCOL®- A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

    May 1, 2011, 00:00

  • PCV21 EFFECTS OF AZILSARTAN MEDOXOMIL VERSUS VALSARTAN AND OLMESARTAN MEDOXOMIL ON THE ACHIEVEMENT OF SYSTOLIC BLOOD PRESSURE GOALS AMONG HYPERTENSIVE PATIENTS WITH DIABETES

    May 1, 2011, 00:00

  • PHP70 PREVENTABLE HOSPITALIZATIONS AND HEALTH INSURANCE COVERAGE IN HARRIS COUNTY, TEXAS

    May 1, 2011, 00:00

  • PRM28 CREATION OF A NEW PSORIASIS QUALITY OF LIFE MEASURE FROM FIVE PREEXISTENT INSTRUMENTS USING RASCH ANALYSIS- THE CALIPSO QUESTIONNAIRE

    May 1, 2011, 00:00

  • PRS9 COMPARISON OF THE BURDEN AND COST DRIVERS OF COPD HOSPITALIZATION BETWEEN HISPANIC AND WHITE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV15 PREDICTORS OF THE COMBINED DIAGNOSIS HYPERLIPIDEMIA AND HYPERTENSION - A NHANES 2007-2008 STUDY

    May 1, 2011, 00:00

  • PRM44 OPTIMUM METHODS FOR PRO TRANSLATION AND LINGUISTIC VALIDATION METHODOLOGY- ONE BACK TRANSLATION OR TWO?

    May 1, 2011, 00:00

  • PSU4 SURGEON'S VOLUME-OUTCOMES RELATIONSHIP FOR LOBECTOMIES AND WEDGE RESECTIONS FOR CANCER USING VIDEO-ASSISTED THORACOSCOPIC TECHNIQUES

    May 1, 2011, 00:00

  • PIH6 THE DEFINITION AND PREVALENCE OF PSYCHOTROPIC POLYPHARMACY IN MEDICAID CHILDREN AND ADOLESCENTS

    May 1, 2011, 00:00

  • DM4 EVALUATION OF CLINICAL LABORATORY-PHARMACY LINKAGE DECISION SUPPORT IN THE USE OF POTASSIUM SUPPLEMENTS

    May 1, 2011, 00:00

  • PMH11 PERFORMANCE OF RISK ADJUSTMENT SCALES IN PREDICTING RISK OF HOSPITALIZATION AMONG DEMENTIA PATIENTS- A MEPS STUDY

    May 1, 2011, 00:00

  • PIN13 IMPACT OF NEWLY DIAGNOSED HEPATITIS C INFECTIONS ON HEALTH CARE COSTS

    May 1, 2011, 00:00

  • PMH41 ECONOMIC EVALUATION OF DESVENLAFAXINE IN THE ACUTE MANAGEMENT OF INPATIENTS WITH MAJOR DEPRESSIVE DISORDER FROM A BRAZILIAN PUBLIC HOSPITAL PERSPECTIVE

    May 1, 2011, 00:00

  • PCV4 TREATMENT PATTERNS, CLINICAL AND ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN ABDOMINAL SURGERY PATIENTS

    May 1, 2011, 00:00

  • PIH1 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH CHRONIC CONDITIONS- EXCESS BURDEN OF COMORBID PHYSICAL AND MENTAL CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PND49 MEASUREMENT CHARACTERISTICS OF THE SF-36 IN PARKINSON'S DISEASE

    May 1, 2011, 00:00

  • PIN27 COST-EFFECTIVENESS ANALYSIS OF THE INTRODUCTION OF ACELLULAR PERTUSSIS IN COLOMBIAN ADOLESCENTS

    May 1, 2011, 00:00

  • PCV92 CHANGES IN THE PREVALENCE, TREATMENT AND CONTROL OF HYPERTENSION IN GERMANY? A CLINICAL-EPIDEMIOLOGICAL EXAMINATION OF 50,000 PRIMARY CARE PATIENTS WITH THE DETECT STUDY

    May 1, 2011, 00:00

  • PIN3 A META-ANALYSIS OF EFFICACY AND SAFETY OF LINEZOLID FOR INFECTED DIABETIC FOOT TREATMENT

    May 1, 2011, 00:00

  • PCV14 DYSPEPSIA AND DISEASE BURDEN AMONG PATIENTS WITH ATRIAL FIBRILLATION (AF)

    May 1, 2011, 00:00

  • PSY58 DISPARITY IN OBESITY MANAGEMENT- UNDER-TREATMENT AMONG ELDERLY POPULATION

    May 1, 2011, 00:00

  • PDB24 DIRECT HEALTHCARE AND INDIRECT WORKLOSS COSTS ASSOCIATED WITH THE ADDITION OF ROSIGLITAZONE (RSG) VERSUS SITAGLIPTIN (STG) THERAPY TO METFORMIN (MET)

    May 1, 2011, 00:00

  • PMS63 SATISFACTION, PREFERENCE AND REASONS FOR BIOLOGIC TREATMENT DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PRM42 VISUALLY EVALUATING THE MEASUREMENT COMPARABILITY BETWEEN PAPER-BASED AND ALTERNATE VERSIONS OF ADMINISTRATION OF THE LUNG FUNCTION QUESTIONNAIRE

    May 1, 2011, 00:00

  • PRS24 IMPACT OF MORBIDITY, PSYCHOLOGICAL DISTRESS AND LUNG FUNCTION ON PHYSICAL FUNCTIONING IN A RETIRED POPULATION

    May 1, 2011, 00:00

  • PMS27 A COST-EFFECTIVENESS ANALYSIS FROM AN INSTITUTIONAL PERSPECTIVE TO COMPARE ZOLEDRONIC ACID WITH STANDARD OF CARE IN THE PREVENTION OF HIP FRACTURES IN PATIENTS WITH OSTEOPOROSIS

    May 1, 2011, 00:00

  • PIN19 COST-BENEFIT ANALYSIS OF POSTPARTUM VACCINATION OF BIRTH MOTHERS WITH INFLUENZA VACCINE

    May 1, 2011, 00:00

  • PND62 MEDICATION POSSESSION RATIO (MPR)- A COMPARISON OF TRADITIONAL MPR AND MODIFIED MPR FOR MULTIPLE SCLEROSIS (MS) PATIENTS PRESCRIBED DISEASE MODIFYING DRUGS (DMDS)

    May 1, 2011, 00:00

  • PMH44 PHYSICAL AND MENTAL HEALTH AS IMPORTANT INPUTS INTO WAGE FUNCTION

    May 1, 2011, 00:00

  • PRS3 RELATIVE EFFECTIVENESS STUDY OF OMALIZUMAB- THE USE OF BEFORE-AFTER COHORT METHODOLOGY FOR COVERAGE WITH EVIDENCE DEVELOPMENT

    May 1, 2011, 00:00

  • PHP51 MORTALITY AFTER SPOUSAL BEREAVEMENT IN BENEFICIARIES OF THE HEALTH PLAN

    May 1, 2011, 00:00

  • PGI10 EXAMINATION OF RESOURCE UTILIZATION PATTERNS ACROSS SUBGROUPS OF GASTROESOPHAGEAL REFLUX DISEASE PATIENTS

    May 1, 2011, 00:00

  • PHP80 RELATIONSHIP OF HERBAL KNOWLEDGE TOWARDS ATTITUDE FORMATION AMONG FUTURE PHARMACISTS

    May 1, 2011, 00:00

  • PND32 HEALTH RESOURCE UTILIZATION AND COSTS FOR MIGRANEURS IN SCOTLAND

    May 1, 2011, 00:00

  • PMD35 SHORT TERM OUTCOMES ASSOCIATED WITH A CHANGE IN REIMBURSEMENT FOR DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE

    May 1, 2011, 00:00

  • PSY47 WILLINGNESS TO PAY (WTP) FOR WEIGHT LOSS COACHING- RESULTS FROM THE POWER TRIAL

    May 1, 2011, 00:00

  • PRM10 IS IT FEASIBLE TO COLLECT QUALITY OF LIFE DATA ELECTRONICALLY IN THIN - A UK GENERAL PRACTICE DATABASE?

    May 1, 2011, 00:00

  • PGI9 COMPARISON OF DIRECT MEDICAL COSTS AND SERVICES BY POINT OF SERVICE AND PRESCRIPTION COST FOR PERSONS WITH HEPATITIS-C WITH AND WITHOUT TREATMENT

    May 1, 2011, 00:00

  • PCN24 FACTORS ASSOCIATED WITH LATE-STAGE PROSTATE CANCER SURVIVAL IN FLORIDA

    May 1, 2011, 00:00

  • PMH7 LIKELIHOOD OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG PERSONS INITIATING THERAPY WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS- EFFECT OF INITIAL SSRI AND OTHER FACTORS

    May 1, 2011, 00:00

  • PRS6 WATERPIPE SMOKING AMONG JORDANIAN ADULTS- PREDICTORS AND CORRELATES

    May 1, 2011, 00:00

  • PMS11 APPLYING THE STRATIFIED PROPENSITY SCORE MATCHING METHOD WHEN ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PUK3 DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    May 1, 2011, 00:00

  • PCN3 CARDIOVASCULAR COMORBIDITIES AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PSY76 TREATMENT OF CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) KNOWLEDGE STUDY (TOCKS)- NOVEL DATA COLLECTION, VIEWING AND DYNAMIC REPORTING MECHANISM

    May 1, 2011, 00:00

  • PSY70 ASSOCIATION OF PROVIDER CONTINUITY WITH HOSPITALIZATION AMONG FLORIDA MEDICAID ENROLLEES WITH SICKLE CELL DISEASE (SCD)

    May 1, 2011, 00:00

  • PMH34 MEASURING THE IMPACT OF PERSISTENCE WITH PSYCHOTROPIC DRUG THERAPY ON TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PND39 MULTIPLE SCLEROSIS PATIENTS REPORT IMPROVEMENTS IN FATIGUE AND COGNITIVE FUNCTIONING AFTER ONE YEAR OF NATALIZUMAB TREATMENT

    May 1, 2011, 00:00

  • PMS16 COST OF RHEUMATOID ARTHRITIS PATIENTS RECEIVING TNF-ANTAGONIST THERAPY FROM THE KOREA NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    May 1, 2011, 00:00

  • PIH28 FATIGUE MANAGEMENT- EXAMPLE AT WOMEN WORKING IN PHARMACY

    May 1, 2011, 00:00

  • PMD22 COST-EFFECTIVENESS ANALYSIS OF THREE WOUND DRESSINGS FOR THE TREATMENT OF PRESSURE ULCERS FROM THE PUBLIC HOSPITAL PERSPECTIVE

    May 1, 2011, 00:00

  • PCN66 COST-MINIMIZATION ANALYSIS OF THE USE OF RASBURICASE IN TUMOR LYSIS SYNDROME IN PEDIATRIC ONCOLOGY

    May 1, 2011, 00:00

  • PIH8 THE ECONOMIC IMPACT ATTRIBUTABLE TO THE INAPPROPRIATE PRESCRIPTION OF BENZODIAZEPINES IN THE ELDERLY LIVING IN THE COMMUNITY

    May 1, 2011, 00:00

  • PHP108 THE CASE OF RARE DISEASE DRUGS BEFORE AND AFTER THE INTRODUCTION OF PRICING BODIES- LESSONS LEARNED FROM BRAZIL AND CANADA, IMPLICATIONS FOR THE UNITED STATES

    May 1, 2011, 00:00

  • PRS37 THE PRICE NEGOTIATION ON PHARMACEUTICALS AFTER THE INTRODUCTION OF POSITIVE LIST SYSTEM IN SOUTH KOREA

    May 1, 2011, 00:00

  • PCV26 EFFECTS OF THIAZOLIDINEDIONES ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS AFTER DRUG-ELUTING STENT IMPLANTATION

    May 1, 2011, 00:00

  • PRM40 ISSUES CONCERNING THE TRANSLATION OF THE WORD ‘HASSLED' IN THE MORISKY MEDICATION ADHERENCE SCALE (MMAS-8)

    May 1, 2011, 00:00

  • PSY59 IMPACT OF OBESITY ON AGE-SPECIFIC PREVALENCE OF CHRONIC DISEASES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PGI12 DOSE VARIATIONS WITH ADALIMUMAB AND INFLIXIMAB IN THE TREATMENT OF CROHN'S DISEASE- A CANADIAN ASSESSMENT

    May 1, 2011, 00:00

  • PCN94 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING- BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY

    May 1, 2011, 00:00

  • PCV17 PREDICTORS OF TIME TO DISCONTINUE BETA-BLOCKER FOLLOWING ACUTE MYOCARDIAL INFARCTION- AN ANALYSIS OF THE MEDICARE 5% NATIONAL SAMPLE DATA 2006-2007

    May 1, 2011, 00:00

  • PND51 THE EFFECT OF THE MEDICARE PART D COVERAGE GAP AND OUT-OF-POCKET BURDEN ON THE USE OF DISEASE MODIFYING DRUGS TO TREAT MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PIN9 BUDGET IMPACT MODEL OF ABACAVIR/LAMIVUDINE FOR TREATMENT OF HIV INFECTED PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PUK2 DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA- A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PDB31 BENEFITS AND COSTS OF CONDUCTING SPONSORED CLINICAL TRIALS IN A PUBLICLY FUNDED NEW ZEALAND HOSPITAL- PRE-TRIAL, TRIAL AND FOLLOW-UP

    May 1, 2011, 00:00

  • PCV64 ADHERENCE TO MEDICATIONS WITH ONCE-A-DAY (QD) AND TWICE-A-DAY (BID) DOSING FORMULATIONS IN ACUTE CORONARY SYNDROME (ACS) PATIENTS

    May 1, 2011, 00:00

  • PCV45 COST-EFFECTIVENESS OF CYP2C9 AND VKORC1 GENOTYPE-GUIDED WARFARIN ANTICOAGULATION CARE- THE IMPLEMENTATION OF DISCRETE EVENT SIMULATION MODEL ON THE NATURAL HISTORY OF VENOUS THROMBOEMBOLISM

    May 1, 2011, 00:00

  • PMH80 UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS WITH BIPOLAR DISORDER- A RETROSPECTIVE CLAIMS-BASED STUDY

    May 1, 2011, 00:00

  • PHP102 WHICH CRITERIA ARE USED IN HEALTH CARE DECISIONMAKING AND PRIORITY SETTING? A LITERATURE REVIEW FOR AN INTERNATIONAL SURVEY OF DECISIONMAKERS

    May 1, 2011, 00:00

  • PRS34 PATIENT SELF-MANAGEMENT OF ASTHMA- A STUDY IN AN EMERGENCY ROOM OF A CHEST HOSPITAL IN DELHI, INDIA

    May 1, 2011, 00:00

  • PCV94 ANTICOAGULANT USE, THE PREVALENCE OF BRIDGING AND RELATION TO LENGTH OF STAY AMONG HOSPITALIZED PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PSS5 WHAT INFLUENCES DENTAL CARE AMONG CHILDREN?

    May 1, 2011, 00:00

  • PCN80 PATIENT PREFERENCES FOR TOXICITIES ASSOCIATED WITH CHEMOTHERAPIES FOR ADVANCED BREAST CANCER

    May 1, 2011, 00:00

  • PRS29 KNOWLEDGE, AWARENESS AND PERCEPTION OF TUBERCULOSES (TB) AMONG STUDENTS RESIDING IN UNIVERSITY HOSTELS

    May 1, 2011, 00:00

  • PRM11 WHY ALGORITHM DOESN'T MATTER IN SYNDROMIC SURVEILLANCE- A COMPARISON OF SYNDROME CLASSIFICATION METHODS

    May 1, 2011, 00:00

  • PSS26 PATIENT'S EVALUATION OF THE QUICKNESS OF ACTION OF GINGIVAL INFLAMMATION TREATMENTS

    May 1, 2011, 00:00

  • PRM19 NON-RESPONSE BIAS IN A SURVEY ASSESSING PATIENTS' MEDICATION AND HEALTH BELIEFS

    May 1, 2011, 00:00

  • PSU21 THE REUSE OF SINGLE-USE SURGICAL DEVICES- EVALUATION OF THE ECONOMIC EVIDENCE

    May 1, 2011, 00:00

  • PUK15 THE COST-EFFECTIVENESS OF LANTHANUM CARBONATE IN THE TREATMENT OF HYPERPHOSPHATEMIA IN DIALYSIS PATIENTS FROM A CANADIAN PERSPECTIVE

    May 1, 2011, 00:00

  • PRM45 PILOT TESTING TRANSLATIONS OF PRO MEASURES WITH SENSITIVE POPULATIONS

    May 1, 2011, 00:00

  • MC1 COMPARISON OF REFILL GAP ANALYSIS METHODOLOGIES IN A POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB OR ETANERCEPT

    May 1, 2011, 00:00

  • PIN1 VACCINE-ASSOCIATED GUILLAIN-BARRE SYNDROME- A PHARMACOVIGILANCE ANALYSIS OF DATA IN THE UNITED STATES' VACCINE ADVERSE EVENT REPORTING SYSTEM (1990-2009)

    May 1, 2011, 00:00

  • PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES

    May 1, 2011, 00:00

  • PIN49 A REVIEW OF EPIDEMIOLOGICAL LITERATURE ON THE BASIC REPRODUCTION NUMBER FOR THE 2009 NOVEL STRAIN OF H1N1

    May 1, 2011, 00:00

  • PCN27 COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES

    May 1, 2011, 00:00

  • PMS46 IMPACT OF ETANERCEPT ON WORK AND ACTIVITY IMPAIRMENT IN EMPLOYED PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PRM18 CAN UTILITIES EXCEED 1.0? EMPIRICAL EVIDENCE OF THE CEILING EFFECT

    May 1, 2011, 00:00

  • PMD3 PARTIAL RESPONDERS IN SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PCN12 RESOURCE UTILIZATION AND PERCEPTIONS OF MAJOR MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML)- RESULTS OF A DELPHI PANEL STUDY

    May 1, 2011, 00:00

  • PHP92 RESULTS OF A PHARMACY MANAGEMENT PROGRAM FOR IMPROVING MEDICATION ADHERENCE

    May 1, 2011, 00:00

  • PIH12 INPATIENT COSTS OF LOW BIRTH WEIGHT AND PRE-TERM INFANTS IN THE UNITED STATES IN 2008

    May 1, 2011, 00:00

  • PIN51 IMPACT OF 2005 MEASLES OUTBREAK IN THE UNITED STATES ON IMMUNIZATION RATE AGAINST MEASLES

    May 1, 2011, 00:00

  • PMS64 PATIENT EXPERIENCE WITH SUBCUTANEOUS ANTI-TNF THERAPY AMONG RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PMH26 MEDICATION ADHERENCE AND HEALTH CARE COSTS AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE

    May 1, 2011, 00:00

  • PHP93 AN EXAMINATION OF HOSPITAL-ACQUIRED CONDITIONS BY AGE AND PAYER IN FIFTEEN STATES, 2008

    May 1, 2011, 00:00

  • PSU11 REDUCTION IN HEALTHCARE UTILIZATION AND EXPENDITURES IN PATIENTS TREATED WITH CATHETER ABLATION FOR ATRIAL FIBRILLATION (AF) IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS36 EXAMINING THE RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG INDIVIDUALS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PND13 BURDEN OF ILLNESS IN THE UNITED STATES FOR PEDIATRIC EPILEPSY PATIENTS WITH PARTIAL ONSET SEIZURES RECEIVING ANTI-EPILEPTIC DRUGS

    May 1, 2011, 00:00

  • PSY56 CONTROLLED SUBSTANCE PRESCRIBING AND UTILIZATION OF PRESCRIPTION DRUG MONITORING PROGRAMS

    May 1, 2011, 00:00

  • PRM32 VALIDITY EVIDENCE AND VALIDATION PRACTICE IN PAPERS PUBLISHED IN VALUE IN HEALTH (1998-2010)- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PDB63 GEOGRAPHIC VARIATION IN DRUG SPENDING AND ADHERENCE PATTERNS FOR MEDICARE BENEFICIARIES WITH DIABETES

    May 1, 2011, 00:00

  • PCN74 UTILISATION OF DRUGS INVOLVED IN TREATMENT OF STAGE I AND STAGE II BREAST CANCER IN SLOVAK REPUBLIC

    May 1, 2011, 00:00

  • PMH40 COST-EFFECTIVENESS AND BUDGET IMPACT OF ADJUNCT QUETIAPINE FUMARATE EXTENDED-RELEASE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH AN INADEQUATE RESPONSE TO PREVIOUS THERAPY

    May 1, 2011, 00:00

  • PMD13 POST INGUINAL HERNIA REPAIR PAIN MANAGEMENT COSTS- A STUDY USING THE PREMIER PERSPECTIVE ™ DATABASE (PPD)

    May 1, 2011, 00:00

  • PCN56 COST-EFFECTIVENESS OF TEMSIROLIMUS FOR METASTIC RENAL-CELL CARCINOMA AND POOR PROGNOSIS PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PUK23 METHODOLOGICAL CONSIDERATIONS FOR COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY

    May 1, 2011, 00:00

  • PMS6 THE PREVALENCE OF BONE FRACTURES IN OSTEOPOROSIS PATIENTS USING PROTON PUMP INHIBITORS

    May 1, 2011, 00:00

  • PCV105 THE INITIATION AND EXTENT OF DOSE TITRATION OF ACE INHIBITORS AND β-BLOCKERS POST ACUTE MYOCARDIAL INFARCTION- A PROSPECTIVE AUDIT

    May 1, 2011, 00:00

  • PIH41 SUCCESSFUL SEXUAL INTERCOURSE- TIME-TO-EVENT MODELING IN A SILDENAFIL TRIAL

    May 1, 2011, 00:00

  • IN4 CARDIOVASCULAR DISEASE SCREENING IN HIV-INFECTED PATIENTS – A COST-EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • DS1 INTEGRATING DATA SOURCES TO CONDUCT COMPREHENSIVE ONCOLOGY BASED OUTCOMES RESEARCH

    May 1, 2011, 00:00

  • PMS13 OSTEOPOROSIS-RELATED FRACTURE COSTS AMONG FEMALE COMMERCIALLY INSURED AND MEDICARE PATIENTS

    May 1, 2011, 00:00

  • PDB16 DIABETES MELLITUS TYPE 2 AND T2DM PLUS HYPERTENSION IN BRAZIL- THE EPIDEMIOLOGIC PROFILE OF THE POPULATION REGISTERED IN THE GOVERNMENT PROGRAM HIPERDIA

    May 1, 2011, 00:00

  • PCN49 THE RELATIONSHIP OF AGE AND SEX WITH COST OF TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE

    May 1, 2011, 00:00

  • PCV31 ASSOCIATION BETWEEN HEART FAILURE AND IN-HOSPITAL MORTALITY IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION

    May 1, 2011, 00:00

  • PCV44 CHANGING COST-EFFECTIVENESS EARLY IN THE PRODUCT LIFE CYCLE- THE EXAMPLE OF CLOPIDOGREL BISULFATE

    May 1, 2011, 00:00

  • PDB27 COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH SAXAGLIPTIN VERSUS METFORMIN COMBINED WITH SULFONYLUREAS IN TYPE-2 DIABETES PATIENTS IN CHILE

    May 1, 2011, 00:00

  • PMH51 BASELINE RESULTS FROM BEAT THE BLUES

    May 1, 2011, 00:00

  • PSU24 AGREEMENT BETWEEN PROMIS DEPRESSION, SLEEP DISTURBANCE, AND FATIGUE CAT MEASURES AND SF-36 SCORES IN A CLINICAL COHORT

    May 1, 2011, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139 (current)
  • 140
  • »